Navigation Links
Antares Pharma Announces Positive Results from Application Site,Study for Anturol

s, Minnesota and Basel, Switzerland.

Safe Harbor Statement

In addition to historical facts or statements or current conditions, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the positive results. Forward-looking statements provide Antares' current expectation or forecasts of future events. Antares' results could differ materially from those reflected in these forward-looking statements due to decisions of regulatory authorities, Antares' ability to execute on its development plans and general financial, economic, regulatory and political conditions affecting the pharmaceutical industry generally. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements, please see the risk factors in Antares' 10Q's, 10K's and other filings made with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Antares undertakes no obligation to update publicly any forward-looking statement.

Contact

Antares Pharma, Inc.
Stephanie M. Baldwin, 609-359-3020
sbaldwin@antarespharma.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 ... ) and Adocia (Euronext Paris: FR0011184241 – ADOC) today ... ultra-rapid insulin, known as BioChaperone Lispro, for treatment in ... Lispro relies on Adocia,s proprietary BioChaperone® technology and is ... Adocia will develop BioChaperone Lispro with the goal of ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... COCONUT GROVE, Fla., April 9, 2012 Med-Tek a developer ... for patients, physicians, employers and their constituents today announces ... According to the United ... through 2004 individuals suffering from ...
... 2012 C8 MediSensors, Inc. ( www.c8medisensors.com ), the ... with diabetes, announced today that it has filed for ... Glucose Monitor™ in Europe. The monitor is currently an ... "The European Union has over 30 ...
Cached Medicine Technology:Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2C8 MediSensors Files for CE Mark Approval, Advancing Plans for 2012 Product Introduction In Europe 2
(Date:12/19/2014)... Thompson HealthDay Reporter ... into the United States -- along with Angelina Jolie,s ... have highlighted cracks in the nation,s public health defense ... report released Thursday. Half of U.S. states are ... disease outbreaks. That was the main conclusion of the ...
(Date:12/19/2014)... The global magnetic resonance imaging (MRI) ... is saturated with numerous players developing innovative technologies. ... as non-invasive nature, MRI systems have seen continued ... healthcare market. Rapid advances in the field imaging ... have greatly expanded the potential of therapeutic applications. ...
(Date:12/19/2014)... 2014 Pain Free Living a leader ... announce a new Superior magnetic necklace using ... the strongest neodymium magnets for the fastest pain relief ... the Superior Magnetics brand for the fastest relief by ... magnetic therapy using Superior Magnetic Jewelry at fairs and ...
(Date:12/19/2014)... Slone Partners , a ... healthcare information technology, and laboratory testing industries, has ... Operating Officer. The announcement comes after a year ... strengthened presence in Boston and several new additions ... breathes the client experience," said Adam Slone, Chief ...
(Date:12/19/2014)... Consilium Staffing, Your Partner in ... for Federal Health Professionals annual meeting in Washington, ... military and federal healthcare providers. , In ... Business Engagement (NVSBE) conference last week in Atlanta, ... vital solution in addressing our nation’s shortage of ...
Breaking Medicine News(10 mins):Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2
... Back New Provider Non-Discrimination Safeguards to Ensure Patient Access ... WASHINGTON, Dec. 4 The American Optometric Association (AOA), ... eye and vision care in America, and eleven other ... (PARCA) today called on President-elect Barack Obama and Congressional ...
... Income Trust (NYSE: UHT ) announced today that ... Marc D. Miller, Senior Vice,President of Universal Health Services, Inc. ... of experience in healthcare leadership roles. He has,served as ... Division,since 2007 and prior to that, served as Vice President ...
... ease sickle-cell disease and thalassemia , ... ... Boston ( www.childrenshospital.org ) and Dana-Farber Cancer Institute have identified ... form of hemoglobin normally made only before birth or by ...
... 4 Dr. Stephen Joffe, Craig Joffe, and,Alan Buckey ... the U.S.,Securities and Exchange Commission. The group previously ... (Nasdaq: LCAV ), which,operates 77 LasikPlus fixed-site ... States. Dr. Joffe is the founder and former ...
... a Common Factor?" , , ... call into question the safety of the Centers for Disease ... concurrently. , , Mitochondrial ... in PLOS One by investigators from the Cleveland Clinic, Johns ...
... of vigorous activity a week , , THURSDAY, Dec. 4 ... in the United States last year met the 2008 ... those people met the Healthy People 2010 physical activity ... , According to the 2008 guidelines, released in October ...
Cached Medicine News:Health News:AOA-Led Group Urges Obama to Increase Health Care Access, Affordability by Combating Provider Discrimination 2Health News:AOA-Led Group Urges Obama to Increase Health Care Access, Affordability by Combating Provider Discrimination 3Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 6Health News:Researchers & Department of Defense Question Multiple Vaccine Administration 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 3
For the quantitative determination of Gamma-GT in serum. Kinetic Reaction measured at 405 nm. Linearity: 600 IU/L at 37C....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for eight hours. Wavelength: 650 nm. Linearity: 16 m...
For the quantitative determination of calcium in serum. Endpoint Reaction Product measured at 570 nm Linearity: 20 mg/dl...
Alanine Aminotransferase (ALT) reagent is used for the quantitative determination of alanine aminotransferase (Glutamate pyruvate transaminase, SGPT) in human serum....
Medicine Products: